Abstract
Children and adolescents with chronic kidney disease (CKD) are at high risk for cardiovascular morbidity and mortality. This review provides a comprehensive overview of the possible risk factors for early atherosclerosis in children with CKD. Endothelial dysfunction, a precursor of atherosclerosis, starts early in renal disease, as indicated by increased carotid artery intima media thickness, carotid arterial wall stiffness, impaired flow mediated dilatation, and coronary artery calcification, which are frequently present in children with CKD. Many risk factors for atherosclerosis, such as hypertension, dyslipidemia, renal bone disease, hyperhomocysteinemia, and uremia-related cardiovascular risk factors are associated with CKD. All of these risk factors are modifiable and optimal clinical management can delay or prevent cardiovascular disease. Another strategy to decrease the risk of premature cardiac disease and death in children with CKD is to slow the progression of renal disease.
Keywords: Atherosclerosis, cardiovascular disease, children, chronic kidney disease, renal failure, risk factors.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Pediatric CKD and Cardivascular Disease
Volume: 14 Issue: 3
Author(s): Osama Safder, Shafiqa Al sharif and Jameela A. Kari
Affiliation:
Keywords: Atherosclerosis, cardiovascular disease, children, chronic kidney disease, renal failure, risk factors.
Abstract: Children and adolescents with chronic kidney disease (CKD) are at high risk for cardiovascular morbidity and mortality. This review provides a comprehensive overview of the possible risk factors for early atherosclerosis in children with CKD. Endothelial dysfunction, a precursor of atherosclerosis, starts early in renal disease, as indicated by increased carotid artery intima media thickness, carotid arterial wall stiffness, impaired flow mediated dilatation, and coronary artery calcification, which are frequently present in children with CKD. Many risk factors for atherosclerosis, such as hypertension, dyslipidemia, renal bone disease, hyperhomocysteinemia, and uremia-related cardiovascular risk factors are associated with CKD. All of these risk factors are modifiable and optimal clinical management can delay or prevent cardiovascular disease. Another strategy to decrease the risk of premature cardiac disease and death in children with CKD is to slow the progression of renal disease.
Export Options
About this article
Cite this article as:
Safder Osama, sharif Al Shafiqa and Kari A. Jameela, Pediatric CKD and Cardivascular Disease, Cardiovascular & Hematological Disorders-Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1871529X14666140401112335
DOI https://dx.doi.org/10.2174/1871529X14666140401112335 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Foreword
Current Pharmaceutical Design Cardiac Arrest in the Catheterization Laboratory
Current Cardiology Reviews Nocturnal Hypertension, Nondipping Phenomenon and Target Organ Damage in Obstructive Sleep Apnea Patients - The Bad and the Worse
Current Respiratory Medicine Reviews Atypical Chemokine Receptors in Inflammatory Disease
Current Molecular Medicine Pleiotropic Effects of Rimonabant: Clinical Implications
Current Pharmaceutical Design Targeted Anti-HER2 Cancer Therapy in Elderly Women Diagnosed with Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Platelets and Platelet Interaction with Progenitor Cells in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology Dexmedetomidine: A Novel Anesthetic Agent for Middle Ear Surgery
Recent Patents on CNS Drug Discovery (Discontinued) Atherosclerosis, Degenerative Aortic Stenosis and Statins
Current Drug Targets Adverse Drug Reactions Amongst Adult Patients Admitted in Lagos State University Teaching Hospital Lagos, Nigeria
Current Drug Safety Barriers to Risk Stratification Accuracy in Ischemic Heart Disease in Women: The Role of Non-Obstructive Coronary Artery Disease
Current Pharmaceutical Design Mst1: Function and Mechanism in Brain and Myocardial Ischemia Reperfusion Injury
Current Neuropharmacology Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets The Entirely Subcutaneous Defibrillator (S-Icd): State of the Art and Selection of the Ideal Candidate
Current Cardiology Reviews Recent Updates on Biological Activities of Oxadiazoles
Mini-Reviews in Medicinal Chemistry Antihypertensive Therapy: Role of Aldosterone Antagonists
Current Pharmaceutical Design Application of Mitochondria-Targeted Pharmaceuticals for the Treatment of Heart Disease
Current Pharmaceutical Design A Novel Therapeutic Strategy Against Vascular Disorders with Chymase Inhibitor
Current Vascular Pharmacology Growing Burden of Diabetes in Sub- Saharan Africa: Contribution of Pesticides ?
Current Diabetes Reviews Vascular Wall Responses to Angioplasty and Stenting: Endothelial Injury, Neointimal Hyperplasia and the Process of Restenosis
Vascular Disease Prevention (Discontinued)